-
Company Insights
NewJBS Science Inc Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our JBS Science Inc Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. JBS Science Inc is engaged in the development and application of circulating cell-free DNA (cfDNA) technology to enhance cancer screening. The company's products includes nucleic acid purification, spike-in DNA control kit, DNA pure clean-up kit, PCR kits, droplet digital PCR kits, urine collection kits, and NGS-related products. The company is headquartered in Doylestown, Pennsylvania, the US. GlobalData's Medical Devices...
-
Company Insights
NewIdbyDNA Inc Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our IdbyDNA Inc Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. IdbyDNA Inc (IdbyDNA) is a metagenomics technology company that strives to develop and commercialize laboratory testing products for diagnosis of infectious diseases. The company offers Explify Respiratory, a next-generation sequencing (NGS) test for screening of respiratory infections; and Explify research specimen (EXPRESS) collection and analysis protocol. It develops Explify Platform, which profiles tens of thousands of microorganisms and pathogens in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Metastatic Adenocarcinoma of The Pancreas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ramucirumab in Metastatic Adenocarcinoma of The Pancreas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Metastatic Adenocarcinoma of The Pancreas Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Oral Cavity (Mouth) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ramucirumab in Oral Cavity (Mouth) Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Oral Cavity (Mouth) Cancer Drug Details: Ramucirumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ramucirumab in Hypopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Hypopharyngeal Cancer Drug Details: Ramucirumab (Cyramza) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ramucirumab in Laryngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Laryngeal Cancer Drug Details: Ramucirumab (Cyramza) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ramucirumab in Oropharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Oropharyngeal Cancer Drug Details: Ramucirumab (Cyramza) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ramucirumab in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Esophageal Cancer Drug Details: Ramucirumab (Cyramza) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Recurrent Head And Neck Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ramucirumab in Recurrent Head And Neck Squamous Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Recurrent Head And Neck...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Thymic Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ramucirumab in Thymic Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Thymic Carcinoma Drug Details: Ramucirumab (Cyramza) is an antineoplastic...